Peter Guenter Appointed to Ipsen's Board of Directors
Ipsen has announced the appointment of Peter Guenter to its Board of Directors as a board member, effective January 28, following the vacancy left by Henri Beaufour, who passed away on November 28.
Peter Guenter brings nearly 40 years of experience as a senior executive in the global pharmaceutical industry. Most recently, he served as CEO of Merck Healthcare and was a member of the Merck Group Executive Board from 2021 to 2025.
"Beyond these leadership roles, Peter is actively involved on various boards in the healthcare and private equity sectors," the French pharmaceutical company further stated.
Following this appointment, Ipsen's Board of Directors will remain composed of 14 members: seven women and seven men, including five independent directors and two directors representing employees.
This decision will be subject to ratification at the next Annual General Meeting of shareholders and, once approved, will be effective for the remainder of Henri Beaufour's term, through to the 2027 shareholders' AGM.
Henri Beaufour is on the board of Ipsen SA, Beech Tree SARL, Mayroy SA and Ipsen Pharma SAS and Legal Manager & Partner at Massa Management SARL.
In his past career Mr. Beaufour held the position of Legal Manager at FinHestia SARL and Legal Manager at Camilia Holding Sarl.
Mr. Beaufour received an undergraduate degree from Georgetown University.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (69.2%);
- neuroscience (20.3%);
- rare diseases (10.5%).
At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide.
Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
![Henri Beaufour](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
